Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $279,118,575 across 8 holdings for the quarter ended 2023-03-31, in a 13F-HR/A filed 2023-05-16.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0001123292-23-000059

Period
2023-03-31
Reported value
$279M
Holdings
8
Top 10 weight
100%
New
1
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BIORA THERAPEUTICS INCnew+1,694,481$4.69M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CAREMAX INCexited-4,467,219-$16.3M
BIORA THERAPEUTICS INCexited-42,362,097-$5.58M
SOCIETAL CDMO INCexited-2,202,420-$3.28M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2023

Share positions as resolved from 13F-HR/A 0001123292-23-000059, largest first. % of portfolio is the value over $279,118,574, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AMRYT PHARMA LTD - SPNR ADRAMRYT PHARMA LTD - SPNR ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 8,857,268 shares; 2023Q1: 8,857,268 shares 8,857,268$129M46.27%0
RVLPQRVL PHARMACEUTICALS PLC ORDINAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 14,600,444 shares; 2023Q1: 14,600,444 shares 14,600,444$16.6M5.96%0Timeline
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,792,114 shares; 2023Q1: 1,792,114 shares 1,792,114$5.54M1.98%0Timeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,694,481 shares 1,694,481$4.69M1.68%new

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC NOTE 7.250%12/0principal103,500,000$58.1M0
OMEROS CORPOMEROS CORP NOTE 5.250% 2/1principal65,136,000$46.5M+7,005,000
Omeros CorpOmeros Corp NOTE 6.250%11/1principal11,005,000$11.1M-10,000,000
PARATEK PHARMACEUTICALS INCPARATEK PHARMACEUTICALS INC Convertible Bondprincipal9,000,000$7.42M0

Sold out in Q1 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CAREMAX INCCAREMAX INC4,467,219$16.3Mshares
BRIDGEBIO PHARMA INCBRIDGEBIO PHARMA INC20,000,000$7.75Mprincipal
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC42,362,097$5.58Mshares
SOCIETAL CDMO INCSOCIETAL CDMO INC2,202,420$3.28Mshares

How Q1 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-23-000057 superseded2023-05-15acceptance time not in the bulk data set
13F-HR/A 0001123292-23-000059 baserestatement2023-05-16acceptance time not in the bulk data set